Moreover, we made equivalent observations, when using CD38+ MM-derived cell lines (OPM-2, MM.1 S, RPMI-8826, U-266) that were treated with the anti-CD38 mAb Daratumumab (Fig. 3C, Supplementary Fig. 2). Here, CD38 is linked to Miyoshi myopathy.